Axogen, Inc. - Common Stock (AXGN)

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Axogen (AXGN) stock surged after Q3 2025 earnings beat estimates. Revenue grew 23.5% to $60.1M, while adjusted EPS of $0.12 crushed forecasts. The company also raised its full-year guidance.

FDA delays Axogen's Avance Nerve Graft BLA review to December 5, after new data submission, while the company raises its full-year revenue outlook.

The FDA's move is largely procedural, says one analyst, but it adds incremental uncertainty.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Axogen Inc (AXGN) surpasses Q2 2025 estimates with strong revenue and EPS growth, raises full-year guidance, sparking a 15.8% pre-market stock surge.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.